Search results
Results from the WOW.Com Content Network
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks ...
The company's market cap has fallen to about $1.9 billion at recent prices. ... Before you buy stock in Recursion Pharmaceuticals, consider this: ... The Today Show.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks ...
Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotech that may have that level of potential. The company harnesses artificial intelligence (AI) for drug discovery, promising to ...
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks ...
By 2015, Recursion had closed its Series A round of funding and signed a research agreement with Sanofi Genzyme. [14] In 2020, the company received $50 million equity investment from Bayer during its Series D funding round. [15] [16] The company listed on the Nasdaq Stock Exchange on April 20, 2021 under the ticker symbol RXRX.